Trials / Active Not Recruiting
Active Not RecruitingNCT06209177
Study of ARO-CFB in Adult Healthy Volunteers
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ARO-CFB in Adult Healthy Volunteers and Adult Patients With Complement-Mediated Kidney Disease
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Accepted
Summary
The purpose of AROCFB-1001 is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ARO-CFB Injection in adult healthy volunteers (HVs). HVs will receive either one or two doses of ARO-CFB or placebo.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-CFB | ARO-CFB for sc injection |
| DRUG | Placebo | sterile normal saline (0.9% NaCl for sc injection) |
Timeline
- Start date
- 2024-04-05
- Primary completion
- 2025-03-31
- Completion
- 2026-03-01
- First posted
- 2024-01-17
- Last updated
- 2026-03-23
Locations
1 site across 1 country: New Zealand
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06209177. Inclusion in this directory is not an endorsement.